United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary ENDOLOGIX UPDATE ON U.S. REGULATORY PROGRESS
ENDOLOGIX UPDATE ON U.S. REGULATORY PROGRESS Reaffirms expectations for FDA approval in the second half of 2004 IRVINE, Calif. (May 4, 2004) – Endologix, Inc. (Nasdaq: ELGX) today provided an update on its recent communication with the FDA concerning its pending PMA Application for its
View HTML
Toggle Summary ENDOLOGIX, INC. REPORTS 2003 FOURTH QUARTER AND YEAR END RESULTS
ENDOLOGIX, INC. REPORTS 2003 FOURTH QUARTER AND YEAR END RESULTS Irvine, Calif. – March 10, 2004 – Endologix, Inc., (Nasdaq: ELGX), developer and manufacturer of the Powerlink® System endoluminal stent graft (ELG) for the minimally invasive treatment for abdominal aortic aneurysms (AAAs),
View HTML
Toggle Summary Endologix Completes $16.3 Million Private Placement
Endologix Completes $16.3 Million Private Placement Irvine, Calif. – March 10, 2004 – Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced the completion of a previously announced
View HTML
Toggle Summary Endologix Announces $16.3 Million Private Placement
Endologix Announces $16.3 Million Private Placement Irvine, Calif. – March 8, 2004 – Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that it has signed definitive agreements to
View HTML
Toggle Summary FOUR-YEAR ITALIAN COMPARATIVE STUDY SUPPORTS ENDOLOGIX Powerlink SINGLE-PIECE DESIGN
FOUR-YEAR ITALIAN COMPARATIVE STUDY SUPPORTS ENDOLOGIX Powerlink SINGLE-PIECE DESIGN Study Data to be Presented at the International Congress Conference Irvine, Calif. - February 11, 2004 - Endologix, Inc. (Nasdaq: ELGX) today announced that data from a four-year retrospective comparative Italian
View HTML
Toggle Summary ENDOLOGIX TO HOST CONFERENCE CALL TO DISCUSS DEVELOPMENT AGREEMENT FOR BIOFOAM
ENDOLOGIX TO HOST CONFERENCE CALL TO DISCUSS DEVELOPMENT AGREEMENT FOR BIOFOAM IRVINE, Calif. (January 10, 2004) - Endologix, Inc. (Nasdaq: ELGX) will host a conference call tomorrow, Tuesday, January 11, 2005 at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) to discuss the details of its
View HTML
Toggle Summary ENDOLOGIX SUBMITS Powerlink PMA TO THE FDA
Irvine, Calif. – January 8, 2004 – Endologix, Inc. (Nasdaq: ELGX) today announced it has filed its completed pre-market approval (PMA) submission with the U.S. Food and Drug Administration (FDA) for the Powerlink® System, an endoluminal stent graft (ELG) for the minimally invasive
View HTML